ReviewOncogene2007
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
Review in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 79 citations in OpenAlex.
- High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.Journal of autoimmunity · 2008Trial
- Strategies to therapeutically modulate cytokine action.Nature reviews. Drug discovery · 2023Review
- Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.Leukemia · 2022Article
- CD45: a niche marker for allotransplantation.Blood · 2022Article
- Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.Leukemia · 2022Article
- A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers.Frontiers in oncology · 2021Article
- IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia.Frontiers in microbiology · 2020Article
- Regulatory T Cells As Potential Targets for HIV Cure Research.Frontiers in immunology · 2018Review
- Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.Frontiers in immunology · 2018Review
- Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Novel TNF-related Apoptotic-inducing Ligand-based Immunotoxin for Therapeutic Targeting of CD25 Positive Leukemia.Targeted oncology · 2016Article
- Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors.BioMed research international · 2014Article
- Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.The Journal of biological chemistry · 2013Article
- Review
- Sam68 modulates the promoter specificity of NF-κB and mediates expression of CD25 in activated T cells.Nature communications · 2013Article
- Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.Current hematologic malignancy reports · 2012Review
- Antibody therapy for Adult T-cell leukemia-lymphoma.International journal of hematology · 2011Article
- Treating rheumatic patients with a malignancy.Arthritis research & therapy · 2011Review
- Immunotherapy for ovarian cancer: what's next?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with (90)Y has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.